Cingulate Receives Complete Response Letter from FDA for CTx-1301
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Cingulate announced that the FDA has issued a complete response letter for its new drug application for CTx-1301 for the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD. The response identified specific Chemistry, Manufacturing and Controls information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301. Cingulate expects a prompt submission to FDA of the requested information addressing issues raised. "We are encouraged that the FDA's response was limited to specific information requests related to CMC and did not currently identify any issues related to the clinical safety or efficacy of CTx-1301," said Cingulate CEO Shane Schaffer. "Our immediate priority is to complete the CMC work already underway with our manufacturing partner; we believe the outstanding requests will be addressed quickly as we move efficiently toward resubmission. Importantly, we have nearly $30 million in cash reserves, which we believe provides sufficient capital to address the issues raised and execute on the resubmission process and continue pre-commercial activities into 2027."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CING?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CING
Wall Street analysts forecast CING stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.300
Low
8.00
Averages
27.33
High
58.00
Current: 5.300
Low
8.00
Averages
27.33
High
58.00
About CING
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cingulate Added to Russell 3000E Index
- Index Inclusion Impact: Cingulate's addition to the Russell 3000E Index is expected to enhance its market visibility and potentially attract more institutional investors, thereby improving its stock performance and liquidity.
- Financial Performance Overview: Cingulate's Q1 financial results indicate a positive growth trend, although specific figures were not disclosed, the market's expectations for its future performance have improved, reflecting investor confidence in its business model.
- Quant Rating Analysis: Seeking Alpha's Quant Rating on Cingulate highlights its competitiveness within the industry, further increasing market attention on its stock, which may lead to greater investor participation.
- Historical Performance Review: Cingulate's historical earnings data shows some volatility in its past financial performance; however, the recent index inclusion may lay the groundwork for more stable growth in the future.
See More
Cingulate Inc. Added to Russell 3000E Index, Enhancing Growth Prospects
- Strategic Index Inclusion: Cingulate Inc.'s addition to the Russell 3000E® Index signifies the company's ongoing evolution as a public entity, expected to enhance visibility among institutional investors, thereby increasing market awareness and laying the groundwork for long-term growth.
- ADHD Market Potential: The U.S. ADHD market boasts approximately 100 million annual prescriptions, with Cingulate's CTx-1301 product candidate currently under the FDA's 505(b)(2) pathway, aimed at addressing the growing adult ADHD demand, which is anticipated to significantly boost the company's revenue potential.
- Innovative Drug Delivery Platform: Cingulate's Precision Timed Release™ (PTR™) platform technology aims to improve patient medication experiences by precisely controlling drug release timing, which is expected to provide a competitive edge in the development of products for ADHD and anxiety disorders.
- Future Development Directions: Cingulate plans to leverage its PTR technology to expand its clinical-stage pipeline by developing additional product candidates in various therapeutic areas, further solidifying its market position in the biopharmaceutical industry.
See More
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
Cingulate Receives Complete Response Letter from FDA for ADHD Drug
- FDA Response Letter: Cingulate Inc. has received a Complete Response Letter from the FDA regarding its New Drug Application for CTx-1301, aimed at treating ADHD, which identified specific requests related to Chemistry, Manufacturing, and Controls (CMC) but raised no concerns about the clinical safety or efficacy of the drug.
- Clear Priorities: CEO Shane J. Schaffer emphasized that the immediate priority is to complete the ongoing CMC work with their manufacturing partner, with expectations to quickly address the outstanding requests and efficiently move towards resubmission.
- Strong Financial Position: The company holds nearly $30 million in cash reserves, which is deemed sufficient to tackle the issues raised by the FDA and to execute the resubmission process while continuing pre-commercial activities into 2027, ensuring competitive positioning in the market.
- Positive Stock Reaction: Following a closing price of $3.60 on Monday, Cingulate's shares rose over 5% in pre-market trading, reflecting market optimism regarding the company's future developments.
See More
Cingulate Receives FDA Response, Plans Prompt Information Submission
- FDA Response Details: Cingulate Inc. received a Complete Response Letter from the FDA, primarily focused on Chemistry, Manufacturing, and Controls (CMC) information requests, without raising concerns regarding the clinical safety or efficacy of CTx-1301, which signals a positive outlook for the company's drug application.
- Strong Financial Position: The company is well-capitalized with nearly $30 million in cash reserves, which is sufficient to address the FDA's requests and execute the resubmission process while continuing pre-commercial activities into 2027, ensuring ongoing business momentum.
- Significant Market Potential: The U.S. ADHD market has approximately 100 million annual prescriptions, with over 20 million diagnosed patients, including 12 million adults, indicating a rapidly growing demand for adult ADHD treatments, positioning Cingulate's products favorably in this expanding market.
- Technological Platform Advantage: CTx-1301 utilizes Cingulate's Precision Timed Release (PTR) platform designed to provide rapid onset and all-day efficacy, with the company's innovative technology poised to significantly improve treatment outcomes in ADHD, enhancing patient medication experiences.
See More
Cingulate Added to Russell 3000E Index
- Index Inclusion Impact: Cingulate's addition to the Russell 3000E Index is expected to enhance its market visibility and potentially attract more institutional investors, thereby improving its stock performance and liquidity.
- Financial Performance Overview: Cingulate's Q1 financial results indicate a positive growth trend, although specific figures were not disclosed, the market's expectations for its future performance have improved, reflecting investor confidence in its business model.
- Quant Rating Analysis: Seeking Alpha's Quant Rating on Cingulate highlights its competitiveness within the industry, further increasing market attention on its stock, which may lead to greater investor participation.
- Historical Performance Review: Cingulate's historical earnings data shows some volatility in its past financial performance; however, the recent index inclusion may lay the groundwork for more stable growth in the future.
See More
Cingulate Inc. Added to Russell 3000E Index, Enhancing Growth Prospects
- Strategic Index Inclusion: Cingulate Inc.'s addition to the Russell 3000E® Index signifies the company's ongoing evolution as a public entity, expected to enhance visibility among institutional investors, thereby increasing market awareness and laying the groundwork for long-term growth.
- ADHD Market Potential: The U.S. ADHD market boasts approximately 100 million annual prescriptions, with Cingulate's CTx-1301 product candidate currently under the FDA's 505(b)(2) pathway, aimed at addressing the growing adult ADHD demand, which is anticipated to significantly boost the company's revenue potential.
- Innovative Drug Delivery Platform: Cingulate's Precision Timed Release™ (PTR™) platform technology aims to improve patient medication experiences by precisely controlling drug release timing, which is expected to provide a competitive edge in the development of products for ADHD and anxiety disorders.
- Future Development Directions: Cingulate plans to leverage its PTR technology to expand its clinical-stage pipeline by developing additional product candidates in various therapeutic areas, further solidifying its market position in the biopharmaceutical industry.
See More
ABIVAX and Others See Significant Stock Gains
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
See More
Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%
- Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
- Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
- Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
- Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.
See More
Cingulate Receives Complete Response Letter from FDA for ADHD Drug
- FDA Response Letter: Cingulate Inc. has received a Complete Response Letter from the FDA regarding its New Drug Application for CTx-1301, aimed at treating ADHD, which identified specific requests related to Chemistry, Manufacturing, and Controls (CMC) but raised no concerns about the clinical safety or efficacy of the drug.
- Clear Priorities: CEO Shane J. Schaffer emphasized that the immediate priority is to complete the ongoing CMC work with their manufacturing partner, with expectations to quickly address the outstanding requests and efficiently move towards resubmission.
- Strong Financial Position: The company holds nearly $30 million in cash reserves, which is deemed sufficient to tackle the issues raised by the FDA and to execute the resubmission process while continuing pre-commercial activities into 2027, ensuring competitive positioning in the market.
- Positive Stock Reaction: Following a closing price of $3.60 on Monday, Cingulate's shares rose over 5% in pre-market trading, reflecting market optimism regarding the company's future developments.
See More
Cingulate Receives FDA Response, Plans Prompt Information Submission
- FDA Response Details: Cingulate Inc. received a Complete Response Letter from the FDA, primarily focused on Chemistry, Manufacturing, and Controls (CMC) information requests, without raising concerns regarding the clinical safety or efficacy of CTx-1301, which signals a positive outlook for the company's drug application.
- Strong Financial Position: The company is well-capitalized with nearly $30 million in cash reserves, which is sufficient to address the FDA's requests and execute the resubmission process while continuing pre-commercial activities into 2027, ensuring ongoing business momentum.
- Significant Market Potential: The U.S. ADHD market has approximately 100 million annual prescriptions, with over 20 million diagnosed patients, including 12 million adults, indicating a rapidly growing demand for adult ADHD treatments, positioning Cingulate's products favorably in this expanding market.
- Technological Platform Advantage: CTx-1301 utilizes Cingulate's Precision Timed Release (PTR) platform designed to provide rapid onset and all-day efficacy, with the company's innovative technology poised to significantly improve treatment outcomes in ADHD, enhancing patient medication experiences.
See More
